Background: Tamoxifen and the citrus flavonoid tangeretin exhibit similar i
nhibitory effects on the growth and invasive properties of human mammary ca
ncer cells in vitro; furthermore, the two agents have displayed additive ef
fects in vitro. In this study, we examined whether tangeretin would enhance
tamoxifen's therapeutic benefit in vivo, Methods: Female nude mice (n = 80
) were inoculated subcutaneously with human MCF-7/6 mammary adenocarcinoma
cells. Groups of 20 mice were treated orally by adding the following substa
nces to their drinking water: tamoxifen (3 x 10(-5) M), tangeretin (1 x 10(
-4) M), tamoxifen plus tangeretin (3 x 10(-5) M plus 1 x 10(-4) M), or solv
ent. Results and Conclusions: Oral treatment of mice with tamoxifen resulte
d in a statistically significant inhibition of tumor growth compared with s
olvent treatment (two-sided P = .001), Treatment with tangeretin did not in
hibit tumor growth, and addition of this compound to drinking water with ta
moxifen completely neutralized tamoxifen's inhibitory effect. The median su
rvival time of tumor-bearing mice treated with tamoxifen plus tangeretin wa
s reduced in comparison with that of mice treated with tamoxifen alone (14
versus 56 weeks; two-sided P = .002), Tangeretin (1 x 10(-6) M or higher) i
nhibited the cytolytic effect of murine natural killer cells on MCF-7/6 cel
ls in vitro, which may explain why tamoxifen-induced inhibition of tumor gr
owth in mice is abolished when tangeretin is present in drinking water. Imp
lications: We describe an in vivo model to study potential interference of
dietary compounds, such as flavonoids, with tamoxifen, which could lead to
reduced efficacy of adjuvant therapy. In our study, the tumor growth-inhibi
ting effect of oral tamoxifen was reversed upon addition of tangeretin to t
he diet. Our data argue against excessive consumption of tangeretin-added p
roducts and supplements by patients with mammary cancer during tamoxifen tr
eatment.